InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc.
CAMBRIDGE, Mass., Oct. 22, 2014 /PRNewswire/ -- InVivo Therapeutics Holdings Corp. (OTCQB: NVIV) based in Cambridge, MA is revolutionizing spinal cord injury (SCI) treatment with their novel Neuro-Spinal Scaffold. This technique has been shown to outperform in tissue regrowth in the spinal cord area when cells are coupled with the scaffold. Made from an FDA approved polymer, the scaffold ultimately breaks down to water and carbon dioxide; making it harmless to the human body. NVIV has recently attracted significant investor attention with the announcement of the enrollment of the first subject in the pilot spinal cord injury trial and the approval of a fourth clinical site for the pilot study. The Company observed a 42% surge in their share price on a volume of 3,759,766 shares against an average daily volume of 355,474 shares on Oct 15, 2014 and 21.35% increase on 1,046,749 shares on Oct 20, 2014 pushing the share price above the 50-day SMA of $0.61. NVIV is still trading well below the 200-day SMA of $1.39; however with IRB approval for two additional clinical sights set to be announced in the coming weeks, a strong 2014 finish is expected for NVIV.
Today's announcement reinforces the Company's commitment to the pilot study and the schedule set by the directors. The Barnes-Jewish Hospital at Washington University was announced as the fourth clinical site, with the study's lead investigator Paul Santiago, MD, an Associate Professor of Neurological Surgery and Orthopedic Surgery at the Washington University School of Medicine in St. Louis. The study has been approved by the FDA to involved six clinical sites (four of which have already been announced) and five patients, to be announced in the coming weeks. Given that no therapy of this kind exists for patients with both acute and chronic SCI, NVIV has positioned itself at the forefront of spinal cord injury research with potential for sensation and even function regeneration in SCI patients
An analyst report which details the current situation, technical analysis and analyst comments can be viewed in its entirety by using the link below. There is no cost obligation required to view this report:
http://bit.ly/-NVIV-AnalystReport
Copy and paste to browser may be required.
Forward-Looking Disclaimer
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Not Financial Advice
BrokerBank Securities, Inc. make no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
Compliance Procedure
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
A full disclaimer can be found by viewing the analyst report.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/invivo-therapeutics-analyst-coverage-initiated-analyst-report-by-brokerbank-securities-inc-453710504.html
SOURCE BrokerBank Securities, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article